Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

17 citing papers in PubMed, 29 citations in OpenAlex.

1. Optimization of preparation method and specificity verification of cat CD19 monoclonal antibody for disease diagnosis and treatment.Heliyon · 2024
   Article
2. Antibody and antibody fragments site-specific conjugation using new Q-tag substrate of bacterial transglutaminase.Cell death discovery · 2024
   Article
3. Current Status of Novel Agents for the Treatment of B Cell Malignancies: What's Coming Next?Cancers · 2022
   Review
4. Nanomedicines in B cell-targeting therapies.Acta biomaterialia · 2022
   Review
5. Maintained partial protection againstClinical & translational immunology · 2022
   Article
6. Nanomedicine for Immunotherapy Targeting Hematological Malignancies: Current Approaches and Perspective.Nanomaterials (Basel, Switzerland) · 2021
   Review
7. Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity.Journal of nanobiotechnology · 2021
   Article
8. B-cell related biomarkers associated with severity of the first demyelinating event of acute optic neuritis.Eye (London, England) · 2020
   Article
9. Pretargeted delivery of PI3K/mTOR small-molecule inhibitor-loaded nanoparticles for treatment of non-Hodgkin's lymphoma.Science advances · 2020
   Article
10. Targeting Two Antigens Associated with B-ALL with CD19-CD123 Compound Car T Cell Therapy.Stem cell reviews and reports · 2020
    Article
11. The Influence of B Cell Depletion Therapy on Naturally Acquired Immunity toFrontiers in immunology · 2020
    Article
12. Construction of a Mammalian IRES-based Expression Vector to Amplify a Bispecific Antibody; Blinatumomab.Iranian journal of pharmaceutical research : IJPR · 2019
    Article
13. The Epigenetic Regulation of Blinatumomab Gene Expression: Tumor Cell-dependent T cell Response against Lymphoma Cells and Cytotoxic Activity.International journal of molecular and cellular medicine · 2019
    Article
14. B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets.Therapeutic advances in neurological disorders · 2018
    Review
15. Heterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic application.Journal of translational medicine · 2017
    Review
16. TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL.mAbs
    Article
17. Antibody-Drug Conjugates: Possibilities and Challenges.Avicenna journal of medical biotechnology
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as